Alnylam Pharmaceuticals Inc (ALNY) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Alnylam Pharmaceuticals Inc (ALNY) has a cash flow conversion efficiency ratio of 0.207x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($163.56 Million) by net assets ($789.18 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Check Alnylam Pharmaceuticals Inc (ALNY) strategic investment index to assess the company's strategic physical and investment asset allocation.
Alnylam Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2002–2025)
This chart illustrates how Alnylam Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. See net assets of Alnylam Pharmaceuticals Inc for net asset value and shareholders' equity analysis.
Alnylam Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Alnylam Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Nokia Corp ADR
NYSE:NOK
|
0.018x |
|
Prudential plc
MX:PUKN
|
0.030x |
|
Garmin Ltd
F:GEY
|
0.058x |
|
Commerzbank AG
XETRA:CBK
|
-0.209x |
|
Bloom Energy Corp
NYSE:BE
|
0.531x |
|
Consolidated Edison Inc
NYSE:ED
|
0.007x |
|
Danone SA
F:BSND
|
0.042x |
|
Skandinaviska Enskilda Banken AB (publ)
ST:SEB-A
|
0.151x |
Annual Cash Flow Conversion Efficiency for Alnylam Pharmaceuticals Inc (2002–2025)
The table below shows the annual cash flow conversion efficiency of Alnylam Pharmaceuticals Inc from 2002 to 2025. For the full company profile with market capitalisation and key ratios, see ALNY company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $789.18 Million | $524.08 Million | 0.664x | +636.00% |
| 2024-12-31 | $67.09 Million | $-8.31 Million | -0.124x | +73.75% |
| 2023-12-31 | $-220.64 Million | $104.16 Million | -0.472x | -113.80% |
| 2022-12-31 | $-158.22 Million | $-541.27 Million | 3.421x | +413.58% |
| 2021-12-31 | $588.20 Million | $-641.69 Million | -1.091x | -80.28% |
| 2020-12-31 | $1.02 Billion | $-614.96 Million | -0.605x | -212.68% |
| 2019-12-31 | $1.44 Billion | $-278.43 Million | -0.194x | +55.22% |
| 2018-12-31 | $1.30 Billion | $-562.62 Million | -0.432x | -99.41% |
| 2017-12-31 | $1.77 Billion | $-382.79 Million | -0.217x | +35.19% |
| 2016-12-31 | $920.22 Million | $-307.70 Million | -0.334x | -123.59% |
| 2015-12-31 | $1.26 Billion | $-189.14 Million | -0.150x | +15.47% |
| 2014-12-31 | $936.27 Million | $-165.64 Million | -0.177x | +30.34% |
| 2013-12-31 | $270.35 Million | $-68.66 Million | -0.254x | +70.55% |
| 2012-12-31 | $134.05 Million | $-115.61 Million | -0.862x | -16.88% |
| 2011-12-31 | $118.00 Million | $-87.07 Million | -0.738x | -38.44% |
| 2010-12-31 | $158.23 Million | $-84.34 Million | -0.533x | -31.48% |
| 2009-12-31 | $177.97 Million | $-72.14 Million | -0.405x | -225.12% |
| 2008-12-31 | $202.12 Million | $65.49 Million | 0.324x | -67.16% |
| 2007-12-31 | $199.17 Million | $196.52 Million | 0.987x | +905.92% |
| 2006-12-31 | $201.17 Million | $-24.63 Million | -0.122x | +54.12% |
| 2005-12-31 | $61.78 Million | $-16.48 Million | -0.267x | +37.09% |
| 2004-12-31 | $46.14 Million | $-19.57 Million | -0.424x | -188.30% |
| 2003-12-31 | $-26.71 Million | $-12.83 Million | 0.480x | +74.62% |
| 2002-12-31 | $-4.65 Million | $-1.28 Million | 0.275x | -- |
About Alnylam Pharmaceuticals Inc
Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute h… Read more